Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W S el-Deiry

Showing results (1-10 of 90) with videos related to

Pageof 9
Sort By:
Current Opinion in Oncology|January 1, 1997
Role of oncogenes in resistance and killing by cancer therapeutic agentsW S el-Deiry
Seminars in Cancer Biology|April 2, 1999
Regulation of p53 downstream genesW S el-Deiry
Cell Death and Differentiation|November 1, 2001
Insights into cancer therapeutic design based on p53 and TRAIL receptor signalingW S El-Deiry
Oncogene|March 6, 1997
Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting regionK Somasundaram, W S El-Deiry
Oncogene|April 25, 2000
Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding siteR Takimoto, W S El-Deiry
International Journal of Cancer|July 29, 1996
In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drugM V Blagosklonny, W S el-Deiry
International Journal of Oncology|April 14, 2000
Cell cycle control as a basis for cancer drug development (Review)E R McDonald, W S El-Deiry
Experimental Oncology|October 17, 2012
Caspase-8 regulation of TRAIL-mediated cell deathR N Crowder, W S El-Deiry
International Journal of Cancer|March 20, 1998
Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cellsM V Blagosklonny, W S El-Deiry
Biochemical and Biophysical Research Communications|March 1, 2000
p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4S Q Xu, W S El-Deiry
Pageof 9

Showing results (1-10 of 90) with videos related to

Sort By:
Pageof 9
Current Opinion in Oncology|January 1, 1997
Role of oncogenes in resistance and killing by cancer therapeutic agentsW S el-Deiry
Seminars in Cancer Biology|April 2, 1999
Regulation of p53 downstream genesW S el-Deiry
Cell Death and Differentiation|November 1, 2001
Insights into cancer therapeutic design based on p53 and TRAIL receptor signalingW S El-Deiry
Oncogene|March 6, 1997
Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting regionK Somasundaram, W S El-Deiry
Oncogene|April 25, 2000
Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding siteR Takimoto, W S El-Deiry
International Journal of Cancer|July 29, 1996
In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drugM V Blagosklonny, W S el-Deiry
International Journal of Oncology|April 14, 2000
Cell cycle control as a basis for cancer drug development (Review)E R McDonald, W S El-Deiry
Experimental Oncology|October 17, 2012
Caspase-8 regulation of TRAIL-mediated cell deathR N Crowder, W S El-Deiry
International Journal of Cancer|March 20, 1998
Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cellsM V Blagosklonny, W S El-Deiry
Biochemical and Biophysical Research Communications|March 1, 2000
p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4S Q Xu, W S El-Deiry
Pageof 9